Free Trial
NASDAQ:JANX

Janux Therapeutics Q2 2023 Earnings Report

Janux Therapeutics logo
$23.14 -0.57 (-2.38%)
As of 09:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Janux Therapeutics EPS Results

Actual EPS
-$0.42
Consensus EPS
-$0.52
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Janux Therapeutics Revenue Results

Actual Revenue
$1.06 million
Expected Revenue
$1.25 million
Beat/Miss
Missed by -$190.00 thousand
YoY Revenue Growth
N/A

Janux Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Tuesday, August 8, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Janux Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Janux Therapeutics Earnings Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
See More Janux Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Janux Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Janux Therapeutics and other key companies, straight to your email.

About Janux Therapeutics

Janux Therapeutics (NASDAQ:JANX), a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

View Janux Therapeutics Profile

More Earnings Resources from MarketBeat